Low molecular weight heparin and cancer survival: clinical trials and experimental mechanisms

被引：0
|
作者：
Ning Zhang
Weihua Lou
Fang Ji
Lihua Qiu
Benjamin K. Tsang
Wen Di
机构：
[1] Shanghai JiaoTong University,Department of Obstetrics and Gynecology, Ren Ji Hospital, School of Medicine
[2] Shanghai Key Laboratory of Gynecologic Oncology,Macau Institute for Applied Research in Medicine and Health3, State Key laboratory of Quality Research in Chinese Medicine
[3] Macau University of Science and Technology,Department of Obstetrics & Gynecology and Cellular & Molecular Medicine, Interdisciplinary School of Health Sciences, University of Ottawa, and Chronic Diseases Program
[4] Ottawa Hospital Research Institute,undefined
来源：
Journal of Cancer Research and Clinical Oncology | 2016年 / 142卷
关键词：
Cancer; Low molecular weight heparin; Survival; Randomized trial; Molecular mechanisms;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1807 / 1816
页数：9
相关论文
共 50 条
  • [31] Antithrombotic therapy with low molecular weight heparin in cancer patients
    Petralia, G
    Kakkar, AK
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2004, 9 (03) : 119 - 124
  • [32] Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism
    Lee, AYY
    Rickles, FR
    Julian, JA
    Gent, M
    Baker, RI
    Bowden, C
    Kakkar, AK
    Prins, M
    Levine, MN
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (10) : 2123 - 2129
  • [33] A critical review of clinical trials for low-molecular-weight heparin therapy in unstable coronary artery disease
    Husted, S
    Becker, R
    Kher, A
    CLINICAL CARDIOLOGY, 2001, 24 (07) : 492 - 499
  • [34] A randomized clinical trial on the antitumoral effects of low molecular weight heparin in the treatment of esophageal cancer
    Kermani, Ali Taghizadeh
    Hosseini, Sare
    Fanipakdel, Azar
    Mashhad, Mona Joudi
    Rezayat, Kambiz Akhavan
    Zardadi, Mahdi
    Gholami, Arezoo
    Javadinia, Seyed Alireza
    Ferns, Gordon A.
    Avan, Amir
    JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (04) : 4191 - 4199
  • [35] Low-molecular-weight heparin in patients with advanced cancer: A phase 3 clinical trial
    Sideras, Kostandinos
    Schaefer, Paul L.
    Okuno, Scott H.
    Sloan, Jeff A.
    Kutteh, Leila
    Fitch, Tom R.
    Dakhil, Shaker R.
    Levitt, Ralph
    Alberts, Steven R.
    Morton, Roscoe F.
    Rowland, Kendrith M.
    Novotny, Paul J.
    Loprinzi, Charles L.
    MAYO CLINIC PROCEEDINGS, 2006, 81 (06) : 758 - 767
  • [36] CLINICAL-TRIALS OF A LOW-MOLECULAR-WEIGHT MATRIX METALLOPROTEINASE INHIBITOR IN CANCER
    BROWN, PD
    INHIBITION OF MATRIX METALLOPROTEINASES: THERAPEUTIC POTENTIAL, 1994, 732 : 217 - 221
  • [37] Heparin, low-molecular-weight heparins, and heparin pentasaccharide - Basic and clinical differentiation
    Hoppensteadt, D
    Walenga, JM
    Fareed, J
    Bick, RL
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2003, 17 (01) : 313 - +
  • [38] EFFECTS OF LOW-MOLECULAR-WEIGHT HEPARIN IN EXPERIMENTAL DIABETIC NEPHROPATHY
    OTURAI, PS
    KOFOEDENEVOLDSEN, A
    DECKERT, T
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1995, 6 (03): : 1045 - 1045
  • [39] Low molecular weight heparin (clexane) significantly ameliorates experimental colitis
    Dotan, I
    Hershkoviz, R
    Karmeli, F
    Rachmilewitz, D
    Peled, Y
    GASTROENTEROLOGY, 1999, 116 (04) : A702 - A702
  • [40] Experimental Thromboprophylaxis with Low Molecular Weight Heparin After Microsurgical Revascularization
    Yousef, Mohamed Abdelhamid Ali
    Dionigi, Paolo
    JOURNAL OF HAND AND MICROSURGERY, 2015, 7 (02) : 256 - 260
12345